TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30316907
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP) - 35μg of ethinylestradiol plus 2mg of cyproterone acetate for 6 cycles (28 days each)
Study: 30316907
Drug: Metformin -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin - 500mg administered twice daily for 6 months
Study: 30316907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo pills during OCP treatment)
Study: 1927064
Drug: NSAID treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID treatment
Study: 16849624
Drug: Ziconotide administered
Normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziconotide administered intrathecally via continuous infusion
Study: 8784096
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (2 IU/m2 day)
Study: 1732485
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral administration of a combination of rapid- and slow-release diclofenac (Voltaren)
Study: 1732485
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intramuscular diclofenac and an oral depot formula
Study: 6370978
Drug: Nomifensine (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (100-150 mg/day)
Study: 6370978
Drug: Imipramine (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100-150 mg/day)
Study: 28513784
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine solution with alcohol
Study: 28513784
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine solution without alcohol
Study: 25599737
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg intravenous infusion within 2 days after transplantation and 3 months later)
Study: 23163418
Drug: Cabergoline (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (1.25 mg)
Study: 19145720
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion programme for parents (test group)
Study: 16257151
Drug: Isoflavone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (300 mg standardized soy extract with 120 mg isoflavones/day)
Study: 16257151
Drug: Estrogen (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (0.625 mg conjugated equine estrogens + placebo)
Study: 8865524
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg bid ticlopidine for 4 weeks
Study: 10221828
Drug: antacid
Normalized name: Antacid
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antacid
Study: 30670280
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate variability biofeedback 15 min daily for three months
Study: 19142552
Drug: Target glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target glucose level of 80-130 mg/dl
Study: 19142552
Drug: Target glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target glucose level of 160-200 mg/dl
Study: 17292730
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of almonds
Study: 17292730
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g of almonds
Study: 17292730
Drug: 90 g
Normalized name: Fora G90 Glucose Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g of almonds
Study: 15592001
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by a bar attachment (combined mucosa-implant-supported overdenture)
Study: 15592001
Drug: Combined mucosa-implant-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined mucosa-implant-supported overdentures
Study: 9538375
Drug: Bepridil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (300 mg/day in 3 doses)
Study: 9538375
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg/day in 3 doses)
Study: 8370371
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg o.d. for 3 weeks, increased to 100 mg o.d. for final 3 weeks
Study: 8370371
Drug: Nicorandil 10
Normalized name: nicorandil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 10 mg b.d. for 3 weeks, increased to 20 mg b.d. for final 3 weeks
Study: 3092601
Drug: Metamizol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol (2.5 g)
Study: 24982069
Drug: TOL-TAZ plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL-TAZ plus metronidazole (1.5 g TOL-TAZ every 8 hours with 500 mg metronidazole every 8 hours)
Study: 11054442
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g every 8 hours)
Study: 22561357
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of oral caffeine
Study: 19886384
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (150 mg) intramuscularly every 2 weeks for 12 weeks
Study: 15064097
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg/day, 6 week treatment)
Study: 10051462
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) therapy (13-15 mg/kg/d)
Study: 31021041
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection, four sessions with 2 weeks intervals
Study: 28131654
Drug: Febuxostat (ULORIC®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (ULORIC® tablet, 80 mg)
Study: 12632617
Drug: Moderate-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose group (M)
Study: 12632617
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (H)
Study: 42577
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E2
Study: 1609525
Drug: Preventive massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive massage ointment administration
Study: 6743779
Drug: Nifedipine capsule
Normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine capsule (Adalat, Bayer) 10 mg
Study: 6743779
Drug: Nifedipine tablets
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine tablets (Taro) 10 mg
Study: 23647409
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg
Study: 2940971
Drug: Ciprofloxacin 1
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1 g
Study: 2940971
Drug: Ciprofloxacin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (various doses)
Study: 2940971
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg every 12 h
Study: 24646100
Drug: KTP laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP laser therapy (0.8W, time on 50 ms, time off 50 ms, 30 s, 532 nm) followed by SRP
Study: 22396084
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous tramadol
Study: 22396084
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous tramadol + 330 mg paracetamol
Study: 20869570
Drug: Placebo matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching sprays
Study: 15671125
Drug: Propranolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (25 mg)
Study: 8813039
Drug: Less suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less suppression of plasma HIV RNA by treatment
Study: 1603387
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg, twice daily for 5 days)
Study: 1603387
Drug: Trimethoprim/sulfamethoxazole (TMP/SMX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg, twice daily for 5 days)
Study: 6399927
Drug: Oral leucine
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral leucine at a dose of 0.2 g per kg per day
Study: 6399927
Drug: Oral leucine
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral leucine
Study: 30188798
Drug: Transdermal T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal T gel targeting lower [400‐550 ng/dL] T range
Study: 30188798
Drug: Transdermal T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal T gel targeting higher [600‐1000 ng/dL] T range
Study: 24983989
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral cholera vaccine VA 1.4 (1.9×10^9 CFU)
Study: 22441135
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy for 8 months in group D (DM (‐), HT (‐))
Study: 22441135
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in group A (DM (+), HT (+))
Study: 22441135
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in all groups
Study: 18243335
Drug: All antipsychotic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antipsychotic treatments
Study: 16012274
Drug: Nocturnal intravenous
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal intravenous TRH 500 microg
Study: 12887812
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 - 90 ml/day) for 8 weeks in Stg
Study: 12887812
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 - 90 ml/day) for 24 weeks in Ltg
Study: 12887812
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Cg) with no lactulose treatment
Study: 1455377
Drug: Chondroprotective therapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroprotective therapy; specific drugs not mentioned; details on dosage and duration not available.
Study: 1455377
Drug: Chondroprotective drugs;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroprotective drugs; specific drugs not mentioned; details on dosage and duration not available.
Study: 26433782
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of cadazolid twice daily for 10 days
Study: 26433782
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of cadazolid twice daily for 10 days
Study: 26433782
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of cadazolid twice daily for 10 days
Study: 25534724
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of vancomycin four times daily for 10 days
Study: 26433782
Drug: All cadazolid
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All cadazolid doses
Study: 15225946
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg
Study: 10726353
Drug: Zoladex (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (GnRH agonist)
Study: 12542601
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without medication)
Study: 7562288
Drug: Amoxicillin prophylaxis
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin prophylaxis (100 mg/kg per day)
Study: 7562288
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no prophylactic antibiotic treatment)
Study: 2265368
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg IV followed by infusion of 20 mg in 400 ml of 5% glucose)
Study: 2265368
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 ml of 5% glucose)
Study: 7005459
Drug: 4-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day course of doxycycline therapy
Study: 7005459
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of doxycycline therapy
Study: 30670270
Drug: Bikram yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bikram yoga intervention (3-5 classes weekly for 16 weeks)
Study: 18690916
Drug: Benzodiazepine hypnotics
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine hypnotics (recommended dose)
Study: 18690916
Drug: Benzodiazepine hypnotics
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine hypnotics (twice the recommended dose)
Study: 18690916
Drug: Zaleplon (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon (10 and 20 mg)
Study: 14680731
Drug: Short-term enoxaparin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term enoxaparin 1 mg/kg subcutaneously twice a day
Study: 14680731
Drug: Short-term unfractionated
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term unfractionated heparin (UFH)
Study: 14680731
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of a fixed-dose enoxaparin 60 mg subcutaneously twice a day
Study: 2768695
Drug: Fluoride-free placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-free placebo gel
Study: 16707912
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin
Study: 20687400
Drug: No metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No metformin
Study: 25975659
Drug: Uninterrupted rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Uninterrupted rivaroxaban (20 mg once-daily)
Study: 24219882
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (transdermal estradiol 1 mg/d, oral estradiol 2 mg/d with or without medroxyprogesterone acetate 5 mg/d)
Study: 23006063
Drug: Profiling group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profiling group (dialysate temperature 35.5°C, variable sodium concentration [150-138 mEq/L], variable UF rate)
Study: 23006063
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dialysate temperature 37.0°C, fixed sodium concentration [138 mEq/L], fixed UF rate)
Study: 11442161
Drug: Medication with
Normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with new anticonvulsive drugs (AEDs) and psychosocial counseling (MED group)
Study: 1531742
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (group M, n = 54, up to 2 mg/kg)
Study: 1531742
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (group M)
Study: 29611221
Drug: Minimally rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally rough implants (Turned surface - Tur)
Study: 29611221
Drug: Moderately rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately rough implants (TiUnite surface - TiU)
Study: 24752682
Drug: Primaquine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 0.5 mg/kg per day for 5 days (150 mg total)
Study: 24752682
Drug: Primaquine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 0.5 mg/kg per day for 7 days (210 mg total)
Study: 24752682
Drug: Primaquine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 0.25 mg/kg per day for 14 days (210 mg total)
Study: 17351280
Drug: Ephedrine HCl
Normalized name: ephedrine HCl
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine HCl (25 mg, 3 times daily) plus caffeine (200 mg, 3 times daily)
Study: 7608645
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy (Control)
Study: 2405804
Drug: Cholestyramine resin
Normalized name: Cholestyramine Resin
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine resin 4 to 12 g twice daily
Study: 30920620
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/d) for 2 weeks
Study: 30920620
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/d) for 2 weeks
Study: 20851843
Drug: IV Δ9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Δ9‐tetrahydrocannabinol (THC) 2.5 mg
Study: 17384438
Drug: Tolvaptan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (30 mg/d)
Study: 11479396
Drug: L-Dopa alone
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Dopa alone
Study: 9692099
Drug: Budesonide 0.2
Normalized name: budesonide 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.2 mg once daily
Study: 9692099
Drug: Budesonide 0.1
Normalized name: budesonide 0.125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.1 mg twice daily
Study: 31959386
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at 0.025 μg kg‐1 min‐1 (Group N1)
Study: 31959386
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at 0.05 μg kg‐1 min‐1 (Group N2)
Study: 31959386
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at 0.075 μg kg‐1 min‐1 (Group N3)
Study: 31959386
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at 0.10 μg kg‐1 min‐1 (Group N4)
Study: 25204974
Drug: Mesenchymal stromal
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal cells (MSCs) treatment
Study: 20739419
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g encapsulated soybean oil/d plus 14.7 g liquid soybean oil/d (control group)
Study: 20739419
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g encapsulated EPA/d plus 14.7 g liquid soybean oil/d (EPA group)
Study: 20739419
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g encapsulated soybean oil/d plus 14.7 g liquid SDA-enriched soybean oil/d (SDA group)
Study: 19202741
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (200 mg of faropenem)
Study: 19202741
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (200 mg of faropenem)
Study: 30832542
Drug: Telemedicine cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine cochlear implant evaluation
Study: 22582483
Drug: Intravenous intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous intralipid 10% infusion (10 cc/kg)
Study: 12134253
Drug: Intrapartum nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapartum nevirapine (200 mg to mother and 2 mg/kg to infant)
Study: 10192340
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (arm 1): 180 cGy per fraction, total dose 5400 cGy, plus 100 mg/m2 infusional cisplatin.
Study: 10192340
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (arm 2): 117 cGy per fraction, total dose 7020 cGy, plus 100 mg/m2 infusional cisplatin.
Study: 10192340
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (arm 1 and arm 2)
Study: 8584992
Drug: Warfarin (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (targeted International Normalized Ratio 2.0 to 3.0) for a further eight weeks
Study: 8584992
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for a further eight weeks
Study: 8584992
Drug: Three months
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three months of warfarin
Study: 26571827
Drug: Fast neutrons
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutrons 6.3 MeV combined with neutron-photon therapy
Study: 23897424
Drug: 15-μg epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-μg epinephrine test dose
Study: 9357205
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler with Spacer (Group II)
Study: 8442971
Drug: midazolam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.6 mg/kg
Study: 31278470
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium injection